Log in

NYSE:CBMCambrex Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$59.99
0.00 (0.00 %)
(As of 12/5/2019)
Add
Compare
Today's Range
$59.99
Now: $59.99
$59.99
50-Day Range
$59.99
MA: $59.99
$59.99
52-Week Range
$33.80
Now: $59.99
$60.29
VolumeN/A
Average Volume218,726 shs
Market Capitalization$2.02 billion
P/E Ratio21.66
Dividend YieldN/A
Beta2.14
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.
Read More
Cambrex logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.03 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP13201110
Phone201-804-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$532.09 million
Cash Flow$3.91 per share
Book Value$19.48 per share

Profitability

Net Income$92.41 million

Miscellaneous

Employees1,732
Market Cap$2.02 billion
Next Earnings DateN/A
OptionableOptionable

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.

Cambrex (NYSE:CBM) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Cambrex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cambrex.

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) issued its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to analyst estimates of $132.78 million. Cambrex had a return on equity of 5.38% and a net margin of 5.96%. The company's revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.76 earnings per share. View Cambrex's earnings history.

What price target have analysts set for CBM?

2 equities research analysts have issued 12-month price targets for Cambrex's shares. Their forecasts range from $60.00 to $60.00. On average, they anticipate Cambrex's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 0.0% from the stock's current price. View analysts' price targets for Cambrex.

Has Cambrex been receiving favorable news coverage?

News articles about CBM stock have trended extremely negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cambrex earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutCambrex.

Who are some of Cambrex's key competitors?

What other stocks do shareholders of Cambrex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), CVS Health (CVS), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Broadcom (AVGO), Walt Disney (DIS) and Under Armour (UAA).

Who are Cambrex's key executives?

Cambrex's management team includes the following people:
  • Mr. Steven M. Klosk, Pres, CEO & Director (Age 62)
  • Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 53)
  • Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 53)
  • Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 41)
  • Mr. James G. Farrell, VP & Corp. Controller (Age 52)

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $59.99.

How big of a company is Cambrex?

Cambrex has a market capitalization of $2.02 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.

What is Cambrex's official website?

The official website for Cambrex is www.cambrex.com.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]

This page was last updated on 5/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.